Stifel 2026 Healthcare Conference - EXELIXIS INC

Explicit Guidance:

• Clinical Event Timelines: Stellar 304 (Phase 3 non-clear cell renal cancer) top-line data expected in the first quarter of next year, driven by slower-than-anticipated event accrual.
• Future Trial Launches: Anticipation of a "second wave" of Zanzalit Nib trials starting shortly, specifically targeting the de novo metastatic frontline space.
• Regulatory Milestones: PDUFA date for Zanzalit Nib in colorectal cancer scheduled for early March of next year (Note: Transcript mentions "early March of Next Year" regarding PDUFA for Zanzalit Nib; context implies the CRC indication PDUFA extension was recent, but the specific March date is linked to the Zanzalit Nib transition context or potentially the CRC PDUFA depending on interpretation of "transition point" phrasing. Correction: Re-reading transcript: "Zanzalit Nib, is... we have a PDUFA date in March of next year...". This likely refers to the CRC indication given the context of the FDA review status discussed immediately prior. The RCC (Stellar 304) data is Q1 next year.
• Long-Term Revenue Replacement: Management projects Zanzalit Nib to replace Cabo (Cabozantinib) revenue by 2031 (post-Cabo exclusivity) with the potential to grow beyond Cabo's peak, aiming for a multi-billion dollar franchise.

Business-Segment Outlook:

• Zanzalit Nib (RCC): Goal is to establish Level 1 evidence to define the standard of care in non-clear cell RCC (Stellar 304) via a large randomized Phase 3, aiming to move from a "hodgepodge" of current therapies to a unified standard.
• Zanzalit Nib (Colorectal): Targeting a $1.5 billion market opportunity in 3rd-line plus patients. Management aims to take share from the Sunlight regimen, TKIs, and broader chemotherapy (approx. 1/3 share each), leveraging a chemo-free, checkpoint-containing oral option with broad activity across liver and non-liver metastasis subgroups.
• Future Pipeline (Stellar 316): Targeting MRD-positive post-adjuvant colorectal cancer patients (20% of population) with high relapse risk (~6 months), aiming to validate MRD-guided treatment intensification (Zanzalit Nib monotherapy or combo with Pembrolizumab) against placebo.
• Pipeline Prioritization: Adoption of a "ruthless" prioritization strategy for early-stage assets; programs failing to demonstrate data robustness for a pivotal study entry within ~12 months will be terminated.
• Franchise Expansion: Active pursuit of a third franchise by 2031 to bridge Cabo expiration, utilizing both internal development and external M&A/BizDev to leverage existing commercial and development scale.

Market and Competitive Outlook:

• Pricing/Dosing Strategy: Implementing dose optimization based on indication and line of therapy (e.g., lowering doses in earlier lines/later lines to balance tolerability vs. efficacy), rather than a static dose.
• Competitive Positioning (RCC): Positioning Zanzalit Nib to capture share in the frontline metastatic space (anticipated "second wave" of trials) and defend share in the second line by highlighting the sequencing advantage over combinations like LightSpark 12, potentially extending Cabo use in the first line to preserve Zanzalit Nib for later lines.
• Competitive Positioning (CRC): Aiming to disrupt the "three-thirds" market split (1/3 Sunlight, 1/3 TKIs, 1/3 Chemo) by offering a broad-label option active across all subgroups, including prior Avastin patients.
• Market Dynamics: Belief that maintenance/monotherapy TKIs can succeed in earlier lines if tolerability is managed via shorter half-life and titratability, addressing historical compliance issues seen with competitors (e.g., SUTENT adjuvant).

Macro / Industry Outlook:

• Labeling Trends: Expectation that FDA labels may become broader for Zanzalit Nib in CRC, moving away from restricted subgroups (e.g., liver metastasis) as data shows efficacy across all subgroups (similar to PARP inhibitors), potentially unlocking larger addressable markets.
• Regulatory Strategy: Preference for defining new standards of care via large randomized trials (Level 1 evidence) rather than relying on single-arm or smaller study data.

Strategic Initiatives:

• Clinical Collaboration Model: Continuing to partner with clinical collaborators to co-fund studies (paying 50%), enabling the company to double the study footprint for the same capital outlay (e.g., moving from 7 pivotal studies to 14+ with "Wave 2").
• Total Opportunity: Targeting $5 billion+ in total opportunity from seven outlined pivotal studies for Zanzalit Nib, with potential to scale further with additional studies.
• M&A Discipline: Commitment to a "thick filter" for external acquisitions, requiring conviction in both biology and commercial potential to avoid value destruction; focus on "commercial differentiation" and "new standard of care" potential over "me-too" drugs.
• Cost Efficiency: Leveraging the "business-like" execution model (discipline, prioritization) to drive value creation and shareholder capital stewardship.

Risks and Headwinds to Outlook:

• Event Accrual: Slower-than-expected event rates in clinical trials can delay top-line data releases (as seen with Stellar 304).
• Compliance/Persistence: Historical challenges with TKI maintenance therapy compliance and persistence could impact data integrity in earlier-line maintenance trials (e.g., Stellar 316).
• Labeling Uncertainty: Regulatory labels may be restricted to subgroups if the company does not demonstrate broad efficacy or if the FDA requires subgroup-specific analysis (e.g., liver vs. non-liver).
• Commercial Execution: Risk of revenue trough or gap if the Zanzalit Nib launch timing or commercial adoption fails to smooth the transition from Cabo's loss of exclusivity in 2031.
• M&A Risk: Potential for value destruction if external acquisitions do not meet the high bar for biological and commercial differentiation.

Management Tone on the Future:

• Confidence: High confidence in commercial execution and clinical execution to transition the company from a single-product to a multi-franchise entity.
• Strategic Clarity: Strong conviction that Zanzalit Nib is not just a replacement for Cabo but a growth engine capable of exceeding Cabo's franchise value if the full pipeline (7+ studies) is realized.
• Operational Philosophy: Emphasis on "running the company like a business, not a biotech," highlighting discipline, prioritization, and capital efficiency as core differentiators.
• Optimism: "Full speed ahead" sentiment regarding the commercial launch in CRC, the upcoming RCC data, and the expansion of the development footprint.

Miscellaneous:

• Dose Optimization: Use of 60mg Zanzalit Nib in combination studies (e.g., LightSpark 34) to optimize benefit-risk profiles for specific combinations and lines of therapy, contrasting with the 100mg dose used in late-line CRC.
• Pipeline Velocity: Expectation of quick decision points (pivotal entry vs. termination) within the next 12 months for early-stage assets.
• Market Education: Goal to build a "thought leader" status across RCC, NET, and CRC franchises to drive cross-indication awareness among prescribers.